Outlook Remains Positive with New Licensing Agreements and Successful Product Launches - Research Report on Restoration Life

Outlook Remains Positive with New Licensing Agreements and Successful Product
 Launches - Research Report on Restoration Life Technologies, Thermo Fisher,
                        Agilent, Quest and PerkinElmer

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 26, 2013

NEW YORK, June 26, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Life
Technologies Corporation (NASDAQ: LIFE), Thermo Fisher Scientific, Inc. (NYSE:
TMO), Agilent Technologies Inc. (NYSE: A), Quest Diagnostics Inc. (NYSE: DGX)
and PerkinElmer Inc. (NYSE: PKI). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Life Technologies Corporation Research Report

On June 19, Life Technologies Corporation (Life Technologies) announced a new
licensing agreement granting Suzhou Ribo Life Sciences (Ribo) exclusive rights
to develop and manufacture siRNA therapeutics in China by using its
Invivofectamine Rx delivery technology. Ribo will formulate proprietary siRNA
molecules in combination with Invivofectamine Rx to create a new platform,
designed to address human diseases with high unmet medical need in the Chinese
healthcare system. Alan Sachs, M.D., Ph.D., Chief Scientific Officer and Head
of Global Research at Life Technologies said, "In our continued effort to
deliver game-changing products and technologies to the world's top medical
researchers, we are pleased to partner with Dr. Liang and Suzhou Ribo Life
Sciences. Invivofectamine Rx is a great example of the type of technology we
will continue to license around the world as we expand our commitment to
clinical research customers." The Full Research Report on Life Technologies
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/d9de_LIFE]

--

Thermo Fisher Scientific, Inc. Research Report

On June 10, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) launched the
Thermo Scientific Orbitrap Fusion Tribrid liquid chromatography-mass
spectrometry (LC-MS) system, which combines its three mass analyzers
-quadrupole, Orbitrap and linear ion trap in a novel "Tribrid" architecture,
and offers unprecedented depth of analysis of complex biological samples. "Our
mission has been to create the highest-performing commercial mass spectrometer
ever built," said Dr. Ian Jardine, Chief Technology Officer, Chromatography
and Mass Spectrometry, Thermo Fisher Scientific. "Additionally, we wanted to
make this power widely accessible to the science community and make it
incredibly easy to use. In creating the Orbitrap Fusion, we have combined and
improved our quadrupole, linear ion trap and Orbitrap technologies in an
ultimately flexible research MS system - to arrive at an entirely new class of
instrument that will transform our customers' science." The Full Research
Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/45ea_TMO]

--

Agilent Technologies Inc. Research Report

On June 21, 2013, Agilent Technologies Inc. (Agilent) introduced the U5303A, a
compact dual-channel PCle digitizer with 12-bit resolution which delivers
unprecedented analog fidelity, high effective number of bits and very low
noise. "By coupling high resolution with high precision, the U5303A is one of
the best products in its class," said Didier Lavanchy, Operation Manager for
Agilent's high-speed digitizers. "Its development leverages innovations that
were first introduced in the 12-bit AXIe digitizer, which was named a 2013
Best in Test winner by Test & Measurement World magazine." The Company
informed that the U5303A two-channel, 12-bit, high-speed PCIe high-speed
digitizer with on-board processing is now available for ordering. The Full
Research Report on Agilent Technologies Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/075f_A]

--

Quest Diagnostics Inc. Research Report

On June 6, 2013, Quest Diagnostics Inc. (Quest) announced that President and
Chief Executive Officer Steve Rusckowski reaffirmed the Company's guidance for
its results from continuing operations, before special items, for full-year
2013. Accordingly, he affirmed that the Company expects revenues to
approximate the prior-year level; earnings per diluted share to be between
$4.35 and $4.55; cash provided by operations to approximate $1 billion; and
capital expenditures to approximate $250 million during full-year 2013. Mr.
Rusckowski stated, "We remain comfortable with our guidance for the full-year
2013 as we are making good progress on all five points of our business
strategy. As we've said, 2013 is a building year and we expect to see
improvements in revenues and earnings versus the prior year starting in the
second half. Second quarter revenues and earnings are expected to be down
versus the prior year, but improved compared to first quarter results." The
Full Research Report on Quest Diagnostics Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/0cb6_DGX]

--

PerkinElmer Inc. Research Report

On June 10, 2013, PerkinElmer Inc. (PerkinElmer) introduced the AxION iQT gas
chromatography tandem mass spectrometer (GC/MS/MS) at the 2013 American
Society for Mass Spectrometry Conference. According to the Company, the new
mass spectrometer provides laboratories with easier to use technology, faster
results, and more specific, selective data needed to make more accurate
decisions faster. "Global regulatory expansion is driving increased adoption
of mass spectrometry as the technology provides greater sample insights for
many industries," said Dusty Tenney, President of Environmental Health at
PerkinElmer. "We've created a new category of mass spectrometry designed to be
faster, smarter, modular and easy to operate and maintain that combines
superior quantitative and identification performance into one instrument,
making this latest generation of technology both user and budget friendly."
The Full Research Report on PerkinElmer Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/2d16_PKI]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.